IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$476.27 USD
+2.99 (0.63%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $476.27 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Zacks News
Luminex (LMNX) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
Luminex's (LMNX) fourth-quarter earnings benefit from higher revenues and solid performance across System Sales, Service and Other Revenues. However, gross margin contraction remains a woe.
DaVita (DVA) Earnings Beat Estimates in Q4, Revenues Miss
by Zacks Equity Research
DaVita (DVA) gains from dialysis services in the United States in Q4.
Has IDEXX Laboratories (IDXX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (IDXX) Outperforming Other Medical Stocks This Year?
Cardinal Health (CAH) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Cardinal Health (CAH) fiscal second-quarter results benefit revenue growth and strong segmental performance. However, contraction in gross margin remains a concern.
Becton, Dickinson (BDX) Q1 Earnings Beat, Revenues Rise Y/Y
by Zacks Equity Research
Becton, Dickinson (BDX) sees softness in BD Medical unit, slashes FY20 view.
ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss
by Zacks Equity Research
Flagship Impella drives ABIOMED's (ABMD) fiscal third-quarter results; FY20 revenue guidance slashed.
Here's Why You Should Retain IDEXX Laboratories Stock Now
by Zacks Equity Research
Investor confidence remains high in IDEXX (IDXX) stock, thanks to solid prospects.
IDEXX (IDXX) Q4 Earnings Top Estimates, Revenues Grow Y/Y
by Zacks Equity Research
The year-over-year upside in IDEXX's (IDXX) revenues was primarily driven by strong global gains in CAG Diagnostics' recurring revenues.
Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 14.29% and 0.92%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Idexx Laboratories (IDXX) Q4 Earnings Expected to Decline
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
IDEXX Launches Cytology Service to Upgrade Veterinary Care
by Zacks Equity Research
IDEXX (IDXX) upgrades veterinary care experience by launching a rapid digital cytology service, thus enabling the provision of faster results.
S&P 500 Up 1000 Points in a Month: 10 Stocks Boosted the ETF
by Sanghamitra Saha
The S&P 500 touched the 3,300 mark on Jan 16, having added 1000 points in less than a month. Which stocks led to the ETF rally.
Top-Ranked Nasdaq-100 ETF at New High: 5 Best Stocks
by Sanghamitra Saha
Likelihood of a soon-to-be-signed U.S.-China trade deal, upbeat holiday season sales expectations and decent earnings have led the Nasdaq-100 ETF to a new high.
IDEXX (IDXX) Tops Q3 Earnings Estimates, Lowers EPS View
by Zacks Equity Research
IDEXX (IDXX) impresses investors with solid third-quarter 2019 results on robust performance across all business segments.
Idexx Laboratories (IDXX) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.73% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Impressive Near-Term Outlook for Medical Instruments Industry
by Urmimala Biswas
Growing medical awareness and economic prosperity enhance the uptake of medical instruments in the emerging economies.
Medical Instruments' Oct 31 Earnings Roster: IDXX, ABMD & More
by Urmimala Biswas
Earnings and revenues for the Medical Instruments sector in the third quarter are likely to have declined sequentially. Read to know how a few companies from the sector might have fared in the period.
Idexx Laboratories (IDXX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for IDEXX Laboratories' (IDXX) Q3 Earnings?
by Zacks Equity Research
Growth in Rapid Assays and Veterinary Software revenues is expected to get reflected in IDEXX's (IDXX) third-quarter results.
Here's Why You Should Hold on to IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX's (IDXX) performance.
IDEXX's Kidney Function Test Included in IRIS Staging Views
by Zacks Equity Research
IDEXX (IDXX) is upbeat about the inclusion and approval of the SDMA-based renal care staging guidelines.
Idexx (IDXX) Up 8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto IDEXX (IDXX) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high on IDEXX Laboratories' (IDXX) prospects.
3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX)
by Zacks Equity Research
Idexx (IDXX) could produce exceptional returns because of its solid growth attributes.